Oppenheimer Increases Vertex Pharmaceuticals (NASDAQ:VRTX) P

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) had its price target raised by Oppenheimer from $350.00 to $410.00 in a research note released on Tuesday morning, The Fly reports. Several other brokerages also recently issued reports on VRTX. SVB Leerink reduced their price target on shares of Vertex Pharmaceuticals from $374.00 to $365.00 and set an […]

Related Keywords

Stuarta Arbuckle , David Altshuler , News Ratings For Vertex Pharmaceuticals Daily , Institutional Trading Of Vertex Pharmaceuticals , Vertex Pharmaceuticals , Steward Financial Group , Vertex Pharmaceuticals Stock Performance , Analyst Recommendations For Vertex Pharmaceuticals , Canaccord Genuity Group , Securities Exchange Commission , Investment Consulting Inc , Old North State Trust , Sandy Spring Bank , Vertex Pharmaceuticals Inc , D More Investments Ltd , Get Rating , Moderate Buy , Exchange Commission , Spring Bank , Investments Ltd , Financial Group , North State Trust , Vertex Pharmaceuticals Daily , Nasdaq Vrtx , Vrtx , Medical , 92532f10 , Boost Price Target , Oppenheimer Holdings Inc ,